Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.80 | 71.70 | -0.80% |
| CAC 40 | 8,150.42 | 58.67 | -0.71% |
| DAX 40 | 24,795.94 | 328.23 | -1.31% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,332.30 | 41.21 | -0.40% |
| HKSE | 25,276.02 | 357.19 | -1.39% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 67,400.90 | 1,001.23 | -1.46% |
| NZX 50 Index | 13,065.40 | 49.68 | -0.38% |
| S&P 500 | 7,553.68 | 56.10 | -0.74% |
| S&P/ASX 200 | 8,673.00 | 72.60 | -0.83% |
| SSE Composite Index | 4,066.56 | 17.42 | -0.43% |